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Visual function improvement using
photocromic and selective blue-violet light
filtering spectacle lenses in patients
affected by retinal diseases
L. Colombo1*, E. Melardi1, P. Ferri1, G. Montesano1, S. Samir Attaalla1, F. Patelli1, S. De Cillà2, G. Savaresi3
and L. Rossetti1
Abstract
Background: To evaluate functional visual parameters using photocromic and selective blue-violet light filtering
spectacle lenses in patients affected by central or peripheral scotoma due to retinal diseases.
Sixty patients were enrolled in this study: 30 patients affected by central scotoma, group 1, and 30 affected by
peripheral scotoma, group 2.
Black on White Best Corrected Visual Acuity (BW-BCVA), White on Black Best Corrected Visual Acuity (WB-BCVA),
Mars Contrast Sensitivity (CS) and a Glare Test (GT) were performed to all patients.
Test results with blue-violet filter, a short-pass yellow filter and with no filters were compared.
Results: All scores from test results increased significantly with blue-violet filters for all patients.
The mean BW-BCVA increased from 0.30 ± 0.20 to 0.36 ± 0.21 decimals in group 1 and from 0.44 ± 0.22 to 0.51 ± 0.
23 decimals in group 2 (Mean ± SD, p < 0.0001 in both cases).
The mean WB-BCVA increased from 0.31 ± 0.19 to 0.38 ± 0.23 decimals in group 1 and from 0.46 ± 0.20 to 0.56 ± 0.
22 decimals in group 2 (Mean ± SD, p < 0.0001 in both cases).
The letter count for the CS test increased from 26.7 ± 7.9 to 30.06 ± 7.8 in group 1 (Mean ± SD, p = 0.0005) and
from 31.5 ± 7.6 to 33.72 ± 7.3 in group 2 (Mean ± SD, p = 0.031).
GT was significantly reduced: the letter count increased from 20.93 ± 5.42 to 22.82 ± 4.93 in group 1 (Mean ± SD,
p < 0.0001) and from 24.15 ± 5.5 to 25.97 ± 4.7 in group 2 (Mean ± SD, p < 0.0001).
Higher scores were recorded with the Blue filter compared to Yellow filter in all tests (p < 0.05).
No significant differences in any test results could be detected between the Yellow filter and the No filter condition.
Conclusions: The use of a combination of photocromic lens with a selective blue-violet light filter showed functional
benefit in all evaluated patients.
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Background
Possible harmful effects of blue light have been known
for half a century and linked to photochemical damage
to retinal tissue and RPE [1, 2].
More specifically, some studies showed that, while lon-
ger blue wavelengths of the visible spectrum (465–495)
are essential for circadian rhythm and a normal visual
function [3–5], blue-violet light could cause an oxygen-
dependent retinal injury acting on specific chromo-
phores (by-products of visual cycle) [6, 7].
The chromophore A2E (N-retinylidene-N-retinyletha-
nolamine) is considered the most important target mol-
ecule. Under blue-violet light exposure conditions (400–
440 nm), this chemical seems to induce the production
of reactive oxygen species and to initiate the activity of
cysteine-dependent proteases, ultimately leading to
apoptotis and cell death [6, 8–14].
One of the main known sources of blue light is the
sunlight (25–35% of the emitted spectrum), but an in-
creasing contribution from indoor illumination has been
recorded in the last 10 years. The widespread
commercialization of high brightness light-emitting di-
odes (LEDs) have strongly changed indoor daily illumin-
ation [15]. In addition, white-light LED (the most
common type of LED) have became the most important
technology for smartphone screens [16], tablet back-
lighted displays and other commonly used devices.
A significant part of a LED-emission spectrum peaks at
450 nm, thus within the wavelength range of blue light.
Shorter wavelength blue light has been reported to
show a pivotal role in glare disability due to direct or
reflected bright light and many attempts have been made
to face this concern with intraocular or spectacle blue-
light-filtering lenses.
Based on the results of Sahel and coworkers’ on the
phototoxic action of blue light on human RPE cells [17],
some optical brands have produced increasingly specific
blue-light-filtering spectacle lenses.
We tested the commercially available TRANSITION X-
TRACTIVE® plus CRIZAL PREVENCIA® (Essilor, France)
spectacle lenses. The purpose of our study was to inves-
tigate whether people with ocular chronic disease char-
acterized by either central or peripheral scotoma could
benefit from their use, in terms of visual acuity, contrast
sensitivity and glare.
Methods
We recruited 60 consecutive patients from the San Paolo
Hospital Eye Clinic in Milan, 30 with central scotoma
(within the 5 central degrees from the fovea) and 30 with
peripheral scotoma (outside the 5 central degrees from the
fovea). Each patient underwent a full ophthalmologic exam-
ination. Specific functional tests were performed: Black on
White Best Corrected Visual Acuity (BW-BCVA), White
on Black Best Corrected Visual Acuity (WB-BCVA), Mars
Contrast Sensitivity (CS) and a Glare Test (GT). BCVA
scores were reported in decimals, while Contrast Sensitivity
and Glare Test results were expressed as number of letters
correctly identified by the patient. Except for the GT, all
other tests were performed with standard charts (Snellen
for BCVAs and Mars for CS). Al evaluations were per-
formed monocularly. To avoid letter memorization we used
different charts when testing with or without the filters,
both for Snellen and Mars charts. The GT was performed
using the testing procedure offered by the MonPack 3 de-
vice (Metrovision, Lille, FR): briefly, the test was performed
at 1 m distance with a + 1.00 spherical added to the best
correction for distance; a letter chart was displayed on the
screen, with letters at increasing distance form a bright light
source directed toward the patient; the number of letters
recognized by the patient was then reported.
On each subject, we performed all the tests with and
without the application of blue-violet light filtering
lenses (TRANSITION X-TRACTIVE® plus CRIZAL PRE-
VENCIA®, Essilor, France). Filter lenses come in 3 differ-
ent colors (grey, brown and green) and, according to
manufacturer instructions, the color selection was based
on the individual subject preference in terms of visual
comfort. These filtering lenses have two technologies:
Transition Xtractive and Crizal Prevencia. The former is
responsible for the photocromic effect. When activated,
these photopigment dyes are able to filter 88–95% of
light up to 430 nm. The latter is an antireflective coating
providing protection against both UV and Blue-Violet
light in the backside and frontside of the lens, filtering
up to 20% of the blue-violet light.
All tests with blue-violet filters were performed after
the activation of the lens by means of a UV light.
In order to compare the effect of the blue-violet filter-
ing lenses with traditional short pass wavelength filters
(yellow filter – 450 nm) a subgroup of 28 patients
underwent the same tests with the two different filtering
lenses and no filter lenses. Each patient was randomized
to one of the 6 possible different testing sequences.
The current study was performed in compliance with the
Declaration of Helsinki and international guidelines. Writ-
ten informed consent was obtained from each participant.
All data were analyzed using linear mixed models that
included nested random effects for subject and eye to
account for correlation of repeated measures on the
same eye (before and after the application of the filtering
lenses) and from the same subject (left and right eye).
CS and GT data were modeled as a count process with a
Poisson error distribution.
Results
We analyzed data from two sets of patients. The first set
was composed of 30 patients with central scotoma: 19
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with Age related Macular Degeneration (AMD), 3 with
Stargardt disease, 2 with ocular albinism, 2 with Retinitis
Pigmentosa (RP) and single cases of optic nerve atrophy,
cone dystrophy, myopic degeneration and diabetic
macular edema.
The second set was composed of patients with periph-
eral scotoma, 29 with RP and 1 with glaucoma. Mean
age was 64 ± 21 for patients with central scotoma and
49 ± 13 for patients with peripheral scotoma. The demo-
graphics are summarized in Table 1.
Among patients, all blue-violet filter colors were uni-
formly represented and no significant association could
be detected between the color and the type of scotoma
(p = 0.82, chi-squared test). Linear mixed models were
used to perform multivariate paired tests, with the inclu-
sion of covariates (i.e. the filter color and the location of
the scotoma), in order to compare test performances be-
fore and after the application of the filtering lenses.
Results are reported in Table 2. Both black on white and
white on black visual acuity increased significantly follow-
ing the application of blue-violet filter lenses. For patients
with central scotoma the mean BCVA increased from
0.30 ± 0.20 to 0.36 ± 0.21 decimals for black on white let-
ters and from 0.31 ± 0.19 to 0.38 ± 0.23 decimals for white
on black (Mean ± SD, p < 0.0001 in both cases). For pa-
tients with peripheral scotoma the mean BCVA increased
from 0.44 ± 0.22 to 0.51 ± 0.23 decimals for black on
white letters and from 0.46 ± 0.20 to 0.56 ± 0.22 decimals
for white on black (Mean ± SD, p < 0.0001 in both cases).
Significant increases were also detected in CS test: the
letter count for the Mars test increased from 26.7 ± 7.9
to 30.06 ± 7.8 in patients with central scotoma
(Mean ± SD, p = 0.0005) and from 31.5 ± 7.6 to
33.72 ± 7.3 in patients with peripheral scotoma
(Mean ± SD, p = 0.031).
Glare was also significantly reduced, as shown by the
results of the GT: the letter count for increased from
20.93 ± 5.42 to 22.82 ± 4.93 in patients with central
scotoma (Mean ± SD, p < 0.0001) and from 24.15 ± 5.5
to 25.97 ± 4.7 in patients with peripheral scotoma
(Mean ± SD, p < 0.0001).
Interactions between the location of the scotoma and the
filter application were used to model the presence of a
potentially differential change in patients with peripheral
scotoma with respect to those with central scotoma, but in
no case we could detect any significantly different behavior
between the two groups in terms of performance increase.
Table 2 also reports the mean individual increase
(expressed as the average of the subject means of the dif-
ferences in the test results for the two eyes) in different
test performances after the application of blue-violet fil-
tering lenses. Of notice, all test results showed an in-
creased performance in every subject tested except for a
reduced white on black BCVA in a single patient with
peripheral scotoma.
Table 3 reports the results of the comparison between
the effect of blue-violet filter and a standard short pass
yellow filter. A subgroup of 28 patients (15 with central
scotoma and 13 with peripheral scotoma) was tested as
previously described. Significant differences could be de-
tected between the Blue-violet filter and the Yellow filter
in all tests, with higher scores recorded with the Blue fil-
ter (p < 0.05). No significant differences in any test could
be detected between the Yellow filter and the No filter
condition.
Discussion
The purpose of our study was to assess potential benefits
derived from photocromic and selective blue-violet light
filtering spectacle lenses in patients with central or per-
ipheral scotoma.
Short term visual function enhancement
Results from statistical analysis of our data show that pa-
tients wearing photocromic and selective blue-violet
light filtering spectacle lenses could improve their visual
performances.
In our study, we evaluated two distinct groups of pa-
tients: subjects with central scotoma, primarily affected
by AMD, and subjects with peripheral scotoma, mostly
due to a severe rod dysfunction in RP.
Table 1 Demographic information: for each of the two groups (central or peripheral scotoma) the table reports the male to female ratio
in the second column, the mean age in the third column and the distribution of the diseases causing the scotoma within each group
Demographics Scotoma M:F Age (Mean ± SD) Disease
Central (N = 30) 12:18 64 ± 21 AMD
Stargardt
Cone Dystrophy
Ocular Albinism
Optic Nerve Atrophy
Degenerative Myopia
Retinitis Pigmentosa
Diabetic CME
19
3
1
2
1
1
2
1
Peripheral (N = 30) 13:17 49 ± 13 Retinitis Pigmentosa
Glaucoma
29
1
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Despite the differences in the pathophysiological mecha-
nisms of these retinal diseases and consequently in the
damage localization within the retinal structures, we could
find statistically significant improvements in both groups
for each parameter: visual acuity (both black on white and
white on black), contrast sensitivity and glare.
Glare is an important factor affecting the quality of life of
patients affected by retinal dystrophies. In RP, for example,
the RPE becomes inadequate to contrast light intraocular
scattering. This, together with progressive death of rods
and cones, leads to an increasing difficulty in facing
light adaptation to light changes in the environment
[18]. Photophobia and consequent glare disability are
therefore unavoidable.
In dry AMD, on the other hand, affected patients ex-
perience a slow reduction in visual acuity due to macular
photoreceptors death and RPE and choriocapillaris de-
generation. This leads to the gradual appearance of a
central scotoma in the visual field of involved eyes and
glare becomes a significant impairment in everyday-life.
Blue-violet light is the interval of visible spectrum carry-
ing the highest energy content and it has been considered
the main responsible for glare vision since its discovery.
Technical specifications from Essilor about Transitions
XTRActive lenses report a screening effect of the 88–95% for
the outdoor blue-violet light and the 34% for the indoor radi-
ation [19]. We can thus speculate that our observations may
be a consequence of such a filtering property of blue light.
All patients tested, both with central or peripheral
scotoma, did not complain about color vision distortion
using the blue-violet filter, as opposed to yellow filters.
Based the curve of sensitivity of the human eye, it might
be hypothesized that such a selectivity for blue-violet
light does not alter the colors perception.
Filtering lenses used in our study might have improved
both visual acuity and contrast sensitivity by cutting a
Table 2 Reports all test results before (column 3) and after (column 4) the application of filters
Test results, Mean (SD) Without
filters
With filters Mean Subject
Increase
p
Scotoma
Central BCVA (Black on White) 0.30 (0.20) 0.36 (0.21) 0.057 (0.03) <0.0001
BCVA (White on Black) 0.31 (0.19) 0.38 (0.23) 0.074 (0.045) <0.0001
Glare Test 20.93 (5.42) 22.82 (4.93) 4.52 (1.70) <0.0001
Contrast Sensitivity 26.7 (7.9) 30.06 (7.8) 3.37 (1.8) 0.0005
Peripheral BCVA (Black on White) 0.44 (0.22) 0.51 (0.23) 0.074 (0.04) <0.0001
BCVA (White on Black) 0.46 (0.2) 0.56 (0.22) 0.098 (0.064) <0.0001
Glare Test 24.15 (5.5) 25.97 (4.7) 3.75 (1.3) <0.0001
Contrast Sensitivity 31.5 (7.6) 33.72 (7.3) 2.25 (1.62) 0.031
Column 5 reports the mean subject increase (expressed as the average of the individual means of the differences in the test results for the two eyes). All results
are reported as Mean (SD). The last column reports the significance of each difference obtained from the linear models described in the Method section. Subjects
are divided in patients with central scotoma (top white rows) and peripheral scotoma (bottom gray rows)
Table 3 Reports the Estimated Difference and Standard Errors (SE) obtained by a randomized trial on NN patients
Test Estimated
Difference
SE p
Comparison
BCVA (Black on White) Blue-violet – Yellow 0.071 0.006 <.0001
Blue-violet – No Filter 0.078 0.005 <.0001
Yellow – No Filter 0.007 0.006 0.4197
BCVA (White on Black) Blue-violet – Yellow 0.083 0.009 <.0001
Blue-violet – No Filter 0.088 0.008 <.0001
Yellow – No Filter 0.004 0.009 0.8778
Glare Test Blue-violet – Yellow 0.186 0.041 <.0001
Blue-violet – No Filter 0.204 0.041 <.0001
Yellow – No Filter 0.018 0.043 0.9123
Contrast Sensitivity Blue-violet – Yellow 0.089 0.036 0.0363
Blue-violet – No Filter 0.103 0.035 0.0094
Yellow – No Filter 0.014 0.037 0.9218
Each row block refers to a different test and each row within a block reports all possible differences in the test results between the Blue-violet filter, the Yellow fil-
ter and no filter correction. All p-values have been calculated with mixed linear models and corrected with the Tukey-Kramer method
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preponderant part of blue-violet glaring radiations, pro-
viding more favorable conditions for efficient visual sig-
nal coding from the residual photoreceptors.
To the best of our knowledge, no published studies have
already explored this topic. Further investigations are
needed to better understand the role of selective filtering
lenses in improving quality of life in patients affected by
different retinal diseases.
Prevention in photoreceptor’s loss
AMD is the most important cause of visual impairment
in the elderly population [20] and dry-AMD accounts
for almost the 90% of the cases [21].
Even though increasing age, genetics and smoking are
well established risk factors for AMD [22, 23], it is still
not clear whether other aspects, including long-term ex-
posure to short wavelength light, could contribute to the
development of the disease [24–27].
This might have significant clinical implications, such
as the preference for either blue-light or UVR only-
filtering intra-ocular lenses in cataract surgery.
The dioptric system of the eye is able to filter UVR light,
with the largest contributions from the cornea (for wave-
lengths below 300 nm) and the lens (300–400 nm or even
larger spectrum intervals when age related opacity is
present) [28, 29]. UVR can induce DNA breakdown and
oxidative stress with the production of reactive oxygen
species (ROS), which may cause oxidative damage to RPE
cells and photoreceptors [30, 31].
Since the discovery of the blue-light hazard, blue
light-filtering artificial lenses have been considered as a
viable option for retinal protection, although the real im-
pact of this procedure has not been definitely proven.
This might be an option for further protection in patients
with retinal diseases undergoing cataract surgery at a young
age, such as in RP patients, that would have to renounce
the protection offered by their natural crystalline lens.
Conclusions
Upon these considerations, a wider use of blue-violet light
filtering spectacle lenses, especially in RP patients or old
people with an increased risk of AMD progression, could
not only represent an important instrument to face visual
impairment due to retinal pathologies, but could play a
complementary role in visual preservation.
Limits of our study are the small sample size and the
short follow up time that does not allow observing the
safety role of a lower retinal exposure to dangerous radia-
tions by the years.
Well designed, long term studies could unveil which
spectrum of visible light is to be filtered according with
the human circadian rhythm and what is the real role of
blue-violet light in the pathogenesis and the progression
of many retinal disease, both degenerative and dystrophic.
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